Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma

Cancer Investigation

Volumn 22, Issue 4, 2004, Pages 505-514

  Jacobs, Andrew D ^a   Otero, Henry ^a   Picozzi Jr , Vincent J ^a   Aboulafia, David M ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Docetaxel; Gemcitabine; Pancreatic cancer

Indexed keywords

ADRENALIN; BRONCHODILATING AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; DIURETIC AGENT; DOCETAXEL; FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ANEMIA; ASCITES; BACKACHE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHOLESTASIS; CLINICAL ARTICLE; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; HUMAN; INOPERABLE CANCER; LIVER TOXICITY; LUNG EMBOLISM; LUNG TOXICITY; MALE; MUSCLE WEAKNESS; NAUSEA; PANCREAS CARCINOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; PANCREATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 8644240004     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200026392     Document Type: Conference Paper

References (39)

1. Jemal, A.; Thomas, A.; Murray, T.; Thun, M. Cancer statistics. CA Cancer J. Clin. 2002, 52 (1), 23-47.
2. Ahlgren, J.D. Chemotherapy for pancreatic carcinoma. Cancer 1996, 78 (3 suppl), 654-663.
3. Burris, H.A. III; Moore, M.J.; Andersen, J.; et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15, 2403-2413.
4. Carmichael, J.; Fink, U.; Russell, R.C.; et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 1996, 73, 101-105.
5. Rothenberg, M.L.; Moore, M.J.; Cripps, M.C.; et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. 1996, 7, 347-353.
6. Bissery, M.C.; Guénard, D.; Guéritte-Voegelein, F.; Lavelle, F. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991, 51, 4845-4852.
7. Abbruzzese, J.L.; Evans, D.; Gravel, D.; et al. Docetaxel (D): a potentially active agent for patients with pancreatic adenocarcinomas (PA). Proc. Am. Soc. Clin. Oncol. 1995, 14, 221 (abstract 561).
8. Preusser, P.; Niederle, N.; Harstrick, A.; et al. Phase II study of docetaxel as first-line chemotherapy in metastatic adenocarcinoma of the pancreas. Proc. Am. Soc. Clin. Oncol. 1999, 18, 297 (abstract 1142).
9. Rougier, P.; Adenis, A.; Ducreux, M.; et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur. J. Cancer 2000, 36, 1016-1025.
10. Androulakis, N.; Kourousis, C.; Dimopoulos, M.A.; et al. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J. Clin. Oncol. 1999, 17, 1779-1785.
11. Spiridonidis, C.H.; Laufman, L.R.; Jones, J.; Rhodes, V.A.; Wallace, K.; Nicol, S. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J. Clin. Oncol. 1998, 16, 3866-3873.
12. Choi, C.W.; Choi, I.K.; Seo, J.H.; et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am. J. Clin. Oncol. 2000, 23, 425-428.
13. Lutz, M.P.; Koniger, M.; Muche, R.; et al. A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer. Z. Gastroenterol. 1999, 37, 993-997.
14. Rubin, J.; Gallagher, J.G.; Schroeder, G.; et al. Phase II trial of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 1996, 78, 1888-1891.
15. Weinerman, B.H.; MacCormick, R.E. A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population. Am. J. Clin. Oncol. 1994, 17, 467-469.
16. DeCaprio, J.A.; Mayer, R.J.; Gonin, R.; Arbuck, S.G. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J. Clin. Oncol. 1991, 9, 2128-2133.
17. Tajiri, H.; Yoshimori, M.; Okazaki, N.; Miyaji, M. Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer. Oncology 1991, 48, 18-21.
18. Crown, J.; Casper, E.S.; Botet, J.; Murray, P.; Kelsen, D.P. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J. Clin. Oncol. 1991, 9, 1682-1686.
19. Hansen, R.; Quebbeman, E.; Ritch, P.; Chitambar, C.; Anderson, T. Continuous 5-fluorouracil (5-FU) infusion in carcinoma of the pancreas: a phase II study. Am. J. Med. Sci. 1988, 295, 91-93.
20. Crino, L.; Mosconi, A.M.; Calandri, C.; et al. Gemcitabine in advanced pancreatic cancer: a phase II trial. Am. J. Clin. Oncol. 2001, 24, 296-298.
21. Ulrich-Pur, H.; Kornek, G.V.; Raderer, M.; et al. A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer 2000, 88, 2505-2511.
22. Casper, E.S.; Green, MR.; Kelsen, O.P.; et al. Phase II trial of gemcitabine (2,2′-difluorodeoxy-cytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs 1994, 12, 29-34.
23. Klein, B.; Sadikov, E.; Mishaeli, M.; Levin, I.; Figer, A. Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer. Oncol. Rep. 2000, 7, 875-877.
24. Okada, S.; Sakata, Y.; Matsuno, S.; et al. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Br. J. Cancer 1999, 80, 438-443.
25. Cascinu, S.; Gasparini, G.; Catalano, V.; et al. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann. Oncol. 1999, 10, 1377-1379.
26. Sherman, W.H.; Fine, R.L. Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology 2001, 60, 316-321.
27. Stathopoulos, G.P.; Mavroudis, D.; Tsavaris, N.; et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann. Oncol. 2001, 12, 101-103.
28. Marruchella, A.; Fiorenzano, G.; Merizzi, A.; Rossi, G.; Chiodera, P.L. Diffuse alveolar damage in a patient treated with gemcitabine. Eur. Respir. J. 1998, 11, 504-506.
29. Pavlakis, N.; Bell, D.R.; Millward, M.J.; Levi, J.A. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997, 80, 286-291.
30. Gupta, N.; Imran, A.; Steinberg, H.; Patel, D.; Nissel-Horowitz, S.; Mehrotra, B. Gemcitabine-induced pulmonary toxicity. Case report and review of the literature. Am. J. Clin. Oncol. (CCT) 2002, 25(1), 96-100.
31. Sauer-Heilborn, A.; Kath, R.; Schneider, C.P.; Höffken, K. Severe non-haematological toxicity after treatment with gemcitabine. J. Cancer Res. Clin. Oncol. 1999, 125, 637-640.
32. Read, W.L.; Mortimer, J.E.; Picus, J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002, 94, 843-847.
33. Merad, M.; Le Cesne, A.; Baldeyrou, P.; Mesurolle, B.; Le Chevalier, T. Docetaxel and interstitial pulmonary injury. Ann. Oncol. 1997, 8, 191-194.
34. Dunsford, M.L.; Mead, G.M.; Bateman, A.C.; Cook, T.; Tung, K. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann. Oncol. 1999, 10, 943-947.
35. Kulke, M.H.; Niedzwiecki, D.; Tempero, M.A.; Hollis, D.R.; Mayer, R.J. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed-dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). Proc. Am. Soc. Clin. Oncol. 2004, 22, 4011.
36. Philip, P.A.; Zalupski, M.M.; Zaitkevicius, V.K.; et al. Phase II study of gemcitabine and cisplatin in the treatment of advanced pancreatic cancer. Cancer 2001, 92 (3), 569-577.
37. Rocha Lima, C.M.S.; Savarese, D.; Bruckner, H.; et al. Irinotecan plus gemcitabine induces both radiographic and CA19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J. Clin. Oncol. 2002, 20, 1182-1191.
38. Berlin, J.D.; Catalano, P.; Thomas, J.P.; Kugler, J.W.; Haller, D.G.; Benson, A.B., III. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 2002, 20, 3270-3275.
39. Abbruzzese, J.L.; Rosenberg, A.; Xiong, Q.; et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody Cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer (abstract). Proc. Ann. Soc. Clin. Oncol. 2001, 20, A518.